United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

organon pharma (uk) ltd - probenecid - oral tablet - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

imported (canada) - probenecid - oral tablet - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

imported (france) - probenecid - oral tablet - 500mg

New Zealand - English - Medsafe (Medicines Safety Authority)

rex medical ltd - levetiracetam 500mg - film coated tablet - 500 mg - active: levetiracetam 500mg excipient: colloidal silicon dioxide croscarmellose sodium magnesium stearate maize starch opadry yellow 03b52573 povidone purified water   - everet tablets are indicated for: · use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation. · monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. · add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme). · add-on therapy in the treatment of primary generalised tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalised epilepsy (ige).

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - levetiracetam, quantity: 500 mg - tablet, film coated - excipient ingredients: maize starch; colloidal anhydrous silica; croscarmellose sodium; povidone; microcrystalline cellulose; purified talc; magnesium stearate; titanium dioxide; iron oxide yellow; macrogol 6000; polyvinyl alcohol; macrogol 3350 - use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation. monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme). add-on therapy in the treatment of primary generalized tonic clonic (pgtc) seizures in adults and children from 4 years of age with idiopathic generalised epilepsy (ige).

New Zealand - English - Medsafe (Medicines Safety Authority)

psm healthcare ltd trading as api consumer brands - levetiracetam 500mg - film coated tablet - 500 mg - active: levetiracetam 500mg excipient: colloidal silicon dioxide croscarmellose sodium magnesium stearate maize starch opadry yellow 85f32004 povidone purified talc - use in epileptic patients aged 6 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation. monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme). add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 6 years of age with idiopathic generalized epilepsy (ige).

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - levetiracetam, quantity: 500 mg - tablet, film coated - excipient ingredients: maize starch; colloidal anhydrous silica; croscarmellose sodium; povidone; microcrystalline cellulose; purified talc; magnesium stearate; titanium dioxide; iron oxide yellow; macrogol 6000; polyvinyl alcohol; macrogol 3350 - use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation. monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme). add-on therapy in the treatment of primary generalized tonic clonic (pgtc) seizures in adults and children from 4 years of age with idiopathic generalised epilepsy (ige).

Canada - English - Health Canada

valeant canada lp / valeant canada s.e.c. - probenecid - tablet - 500mg - probenecid 500mg - uricosuric agents

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - amoxicillin trihydrate 575mg equivalent to amoxycillin 500 mg;   - capsule - 500 mg - active: amoxicillin trihydrate 575mg equivalent to amoxycillin 500 mg   excipient: gelatin colloidal anydrous silica magnesium stearate purified talc sodium starch glycolate - amoxicillin should be used in accordance with local antibiotic-prescribing information guidelines and local susceptibility data. amoxicillin may be useful in instituting therapy prior to bacteriology; however bacteriological studies to determine the causative organisms and their sensitivity to amoxicillin should be performed. susceptibility to amoxicillin will vary with geography and time and local susceptibility data should be consulted where available and microbiological sampling and susceptibility testing performed where necessary. treatment of infection: amoxicillin is indicated in the treatment of infections due to susceptible organisms. skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e. coli. respiratory (acute and chronic): h. influenzae; streptococcus; s. pneumoniae; staphylococcus, non-penicillinase-producing; e.coli. genitourinary tract (complicated and uncomplicated, acute and chronic): e.coli, p. mirabilis and s. faecalis. gonorrhoea: n. gonorrhoeae (non-penicillinase producing). prophylaxis for endocarditis: amoxicillin may be used for the prevention of bacteraemia, associated with procedures such as dental extraction, in patients at risk of developing bacterial endocarditis, such as those with a prosthetic heart valve or those who have previously had endocarditis.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - amoxicillin trihydrate 573.96mg equivalent to amoxycillin 500 mg - capsule - 500 mg - active: amoxicillin trihydrate 573.96mg equivalent to amoxycillin 500 mg excipient: allura red ac   brilliant blue fcf   colloidal silicon dioxide croscarmellose sodium gelatin phloxine b quinoline yellow stearic acid sunset yellow fcf titanium dioxide